AVITA Medical, Inc.
HealthcareNASDAQ:RCEL · NASDAQ Capital Market
-$0.06 today
Vol 0.26M · Avg 0.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
291.8%
avg -175.4%
ROIC
-111.4%
avg -86.0%
ROA
-86.2%
avg -72.7%
Analysis
ROE is currently the strongest return metric at 291.8% versus its period average of -175.4%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Cary G. Vance | Chief Executive Officer, President & Executive Director | $891,974.00 | — | 60 | $40,771.00 | 0.16% |
David O'Toole | Chief Financial Officer | $638,256.00 | — | 67 | $152,927.00 | 0.62% |
Nicole Linda Kelsey | Chief Legal & Compliance Officer, Corporate Secretary and Interim SVP of Human Resources | $573,061.00 | — | 59 | $98,390.00 | 0.40% |
Katie Bush | Senior Vice President of Scientific & Medical Affairs | — | — | — | — | — |
Niraj Doshi | Senior Vice President of Global Operations | — | — | — | — | — |
Ben Atkins | Vice President of Investor Relations & Corporate Communications | — | — | — | — | — |
David Melbye | Senior Vice President of Operations | — | — | — | $152,927.00 | 0.62% |
Ron Lagerquist | Senior Vice President of Quality Assurance & Regulatory Affairs | — | — | — | — | — |
Debbie Garner | Senior Vice President of Global Marketing & Strategy | — | — | — | — | — |
Jessica Ekeberg | Director of Investor Relations | — | — | — | — | — |
Robin VanDenburgh | Senior Vice President of U.S. Commercial Sales | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
13
$255,363.00
Sells
0
$0.00
Net Sentiment
+$255,363.00
Net buying
Most Active
O'Toole David D
6 transactions
1–10 of 13
Analysis
Insiders reported 13 buys worth $255,363.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $255,363.00. O'Toole David D was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -23.9% | +48.3% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -23.9% over three years. Forward estimates point to Revenue at +48.3% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Quipt Home Medical Corp.
QIPT
$162.30M
FONAR Corporation
NASDAQ:FONR
$117.76M
Hyperfine, Inc.
NASDAQ:HYPR
$114.53M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
Xtant Medical Holdings, Inc.
AMEX:XTNT
$61.72M
InspireMD, Inc.
NSPR
$34.19M
Who manages RCEL?
AVITA Medical, Inc. (RCEL) lists 11 active executives. The top listed executive is Cary G. Vance, Chief Executive Officer, President & Executive Director.
Are RCEL insiders buying or selling?
Recent insider activity shows net buying of $22.77M.
Explore More
Continue the stock analysis
Jump to another research area for this company.